- Visibility0
- Citations0
- Sentiment50
- Site quality87
- AI readiness50
AI assistants do not name BioAtla in any of their 60 answers. BioAtla has an overall score of 30 out of 100, ranking 1,268th of 2,047 companies. Its website passes 7 out of 14 technical checks for readiness by AI tools.
We asked 15 unbranded questions about the healthcare market: none named BioAtla. AI assistants named it in none of 60 answers. The typical healthcare company is named in 3.3% of answers. By how often it is named, BioAtla ranks 69 of 105 in its sector.
Named fewer than three times in total. Read this as a sign that AI assistants rarely bring this company up, not as an exact comparison with its rivals.
Every dot is a company in the study. Hover one to see it; click to open its report.
This companySame sectorEvery other companyNever named
Five parts, each scored out of 100.
How often AI assistants name the company
How often AI uses the company's own website as a source
How positively AI describes the company
How well built the website's own pages are
How easily AI tools can read and use the website
Visibility is calculated from the answers on this page. How the score is built.
105 companies in this sector. The line on each bar is the typical company.
How the mentions in these answers were split between this company and its rivals
Answers naming it, out of answers received
What this website publishes for an AI agent to read, use and buy from, on a scale of six levels.
- 0
- 1
- 2
- 3
- 4
- 5
Level 1: Basic web presence. Two of robots.txt, a sitemap and Link headers are in place.
- Content Signals
Show every check, for your technical teamHide the checks
- study: 92.0%robots.txtPassed
A valid robots.txt with crawl rules at the site root.
- study: 86.8%SitemapPassed
An XML sitemap listing the pages, ideally referenced from robots.txt.
- study: 0.3%Link headersNot met
Send Link headers such as rel="api-catalog" or rel="describedby" on the homepage.
- study: 5.5%DNS for AI DiscoveryNot present
Advertise agent endpoints with SVCB records under _agents.
- study: 1.9%Markdown negotiationNot met
Return a markdown version when asked with Accept: text/markdown, for example at the CDN.
- study: 25.1%llms.txtPassed
An llms.txt that tells language models what the site offers.
- study: 93.4%AI bot rulesPartly met
Add explicit robots.txt groups for the main AI crawlers.
- study: 1.4%Content SignalsNot met
Add a Content-Signal line for search, ai-input and ai-train to robots.txt.
- study: 0.2%Web Bot AuthNot present
Only relevant if you run your own agents or crawlers: publish a signing key directory.
- study: 0.3%API CatalogNot met
List public APIs in a linkset at /.well-known/api-catalog.
- study: 11.8%OAuth discoveryPartly met
Publish OpenID Connect or OAuth server metadata under /.well-known.
- study: 10.3%OAuth Protected ResourcePassed
Metadata telling agents which authorization server to use.
- study: 0.0%auth.mdNot met
Publish an auth.md describing how agents sign in.
- study: 0.2%MCP Server CardNot met
Offer an MCP server and publish its server card under /.well-known.
- study: 0.1%A2A Agent CardNot met
Publish an agent card at /.well-known/agent-card.json.
- study: 0.2%Agent SkillsNot met
Publish a skills index with the main tasks agents can do.
- study: 33.7%WebMCPCould not check
Register key actions such as search or cart as WebMCP tools.
- study: 0.1%ARD manifestNot met
Publish an ai-catalog.json listing every agent interface.
Score 42 of 100 · 97% of checks could run · checked on October 5, 2026 · www.bioatla.com · 2,047 companies scanned
7 of 14 passed. This list is for your technical team. The percentage is how many companies in the study pass each check.
These 14 checks ran during the audit and are what the AI readiness part of the overall score counts. The scan above ran later and is stricter on Link headers and Markdown, so a check can pass here and not there.
Show the 14 checksHide them
- Passedrobots.txt publishedstudy: 85.0%
- PassedXML sitemapstudy: 73.2%
- PassedHTTP Link headers (RFC 8288)study: 29.0%
- Not metMarkdown content negotiationstudy: 8.3%
- Passedllms.txt publishedstudy: 21.7%
- PassedToken budget (page weight)study: 95.2%
- Not metExplicit AI bot rulesstudy: 13.0%
- Not metAPI Catalog (.well-known/api-catalog)study: 0.2%
- PassedOAuth Authorization Server discoverystudy: 10.1%
- PassedOAuth Protected Resource discoverystudy: 9.3%
- Not metMCP Server Cardstudy: 0.0%
- Not metA2A Agent Cardstudy: 0.0%
- Not metWebMCP toolsstudy: 4.2%
- Not metAgent Skills declaredstudy: 0.0%
This website sets no rules for any AI crawler by name, like 84% of the websites whose rules we could read. Every AI crawler follows its general rules.
- GPTBotallowed
- ClaudeBotallowed
- Anthropic-AIallowed
- Google-Extendedallowed
- Applebot-Extendedallowed
- Meta-ExternalAgentallowed
- FacebookBotallowed
- Bytespiderallowed
- CCBotallowed
- Diffbotallowed
- Omgilibotallowed
- OAI-SearchBotallowed
- Claude-SearchBotallowed
- PerplexityBotallowed
- Applebotallowed
- Amazonbotallowed
- YouBotallowed
- ChatGPT-Userallowed
- Claude-Userallowed
- Perplexity-Userallowed
- DuckAssistBotallowed
- MistralAI-Userallowed
Read from the website’s own rules file (robots.txt). An asterisk marks a crawler the file names. The rest follow its general rules. “Partly” means only some pages are blocked.
How many times each website was listed as a source in these answers
In the study as US-listed.
- What can limit the effectiveness of antibody-based biologic drugs in oncology?
- How do conditionally active biologics compare to traditional monoclonal antibodies for cancer therapy?
- What are the most promising new approaches in oncology biologic therapeutics?
- What are typical cost ranges for advanced oncology biologic treatments in the US?
- Clinical applications of tumor microenvironment-targeted biologic therapies in oncology
- Alternatives to antibody-based therapeutics for treating solid tumors
- What other modalities exist for targeting the tumor microenvironment in cancer treatment?
- Antibody-drug conjugates vs. bispecific antibodies in late-stage oncology treatments
- Is investing in next-generation cancer biologics worth it for oncology practices?
- How to manage adverse events associated with targeted biologic cancer therapies
- Are novel antibody-based therapeutics effective for patients with resistant solid tumors?
- Insurance coverage options for novel biologic agents used in cancer care
- When should conditionally active biologics be considered in metastatic cancer management?
- Best biologic agents for targeting solid tumors in advanced cancer patients
- Latest developments in improving the therapeutic index of targeted cancer biologics
Columns, left to right: OpenAI, Claude, Perplexity, Gemini. The AI assistants often disagree. Across the study, on 40% of the questions where a company is named, only one of the four names it.